Bicycle Therapeutics plc (BCYC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Bicycle Therapeutics plc (BCYC) is down 39.3% since the beginning of the year. At $4 per share, BCYC is trading 54.1% below its 52-week high of $9. Investors who bought $1,000 worth of BCYC shares 5 years ago would now be looking at an investment worth $149.

Bicycle Therapeutics plc (BCYC) has returned -39.27% so far this year and -48.19% over the past 12 months.

Based on dividend-adjusted daily data since May 23, 2019, BCYC's average daily return is +0.04%, while the average monthly return is +0.27%. At this rate, an investment would double in approximately 21.4 years.

Historically, 44% of months were positive and 56% were negative. The best month was Sep 2019 with a return of +55.2%, while the worst month was Apr 2022 at -46.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.

On a daily basis, BCYC closed higher 47% of trading days. The best single day was Jan 14, 2021 with a return of +28.5%, while the worst single day was Apr 11, 2022 at -38.7%.

Bicycle Therapeutics plc has an annualized alpha of -3.96%, beta of 0.91, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 24, 2019.

• This stock participated in 137.80% of S&P 500 Index downside but only 33.20% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BCYC ranks 5 for risk / return — in the bottom 5% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Bicycle Therapeutics plc (BCYC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Bicycle Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bicycle Therapeutics plc was 92.97%, occurring on Jun 2, 2026. The portfolio has not yet recovered.

The current Bicycle Therapeutics plc drawdown is 92.97%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Bicycle Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Bicycle Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.